CorneaGen Releases New DSEK Surgery Device to Help Streamline DSEK Surgeries

CorneaGen announced the release of the EndoSerter-PL, a new FDA approved, single-use graft insertion device preloaded with processed tissue to help streamline DSEK surgeries.

“We’re incredibly excited to deliver the EndoSerter-PL, our latest innovation in advancing the next generation of cornea care,” Bernie Iliakis, President of CorneaGen, said in a company news release. “We strive every day to better serve surgeons, patients, donor families, and industry partners through constant innovation in tissue processing technology and surgical devices.”

“Efficacy and safety are critical for surgery” said Edward Holland, MD, Director of Cornea Services at Cincinnati Eye Institute. “With the tissue pre-loaded, surgery is significantly faster and there is less risk to mishandling of the graft. Experienced DSEK surgeons who used the original EndoSerter insertion device are going to appreciate the benefits if the EndoSerter-PL.”

The EndoSerter-PL will be showcased in booth #944 at ASCRS 2022, from April 22-26. Notable product demonstrations will be performed by Dr. Holland on April 23, at 1:00 p.m., and John Berdahl, MD, on April 24, at 10:00 a.m. 

In addition to evolving tissue processing and products, CorneaGen works as an advocate for patients. Through efforts to simplify payor reimbursement and its many industry relationships, CorneaGen serves as partner in helping all those impacted by corneal disease.  

CorneaGen remains committed to transforming lives, helping deliver the gift of sight to tens of thousands of people in the U.S. every year.